IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit: 1624 Examiner: B. Coleman

December 27, 2001

11046 U.S. 949 10/026949

In re Patent Application of

Inventors:	Y. HAMIED et al)	
Appln. No.:	Unknown)	INFORMATION
Filed:	December 27, 2001)	INFORMATION DISCLOSURE STATEMENT
For:	PHARMACEUTICAL COMPOSITIONS CONTAINING NEW POLYMORPHIC FORMS OF OLANZAPINE AND USES THEREOF)))	STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

33396-177202

Sir:

Atty. Dkt.:

In accordance with the duty of disclosure, the applicants inform the Examiner of the documents cited during prosecution of the parent application, 09/540,749. Applicants also notify the Examiner of newly cited references which are listed on the attached copy of the PTO-1449. Applicants respectfully request the Examiner to initial and return a copy of the PTO-1449's as indication that the references have been considered.

Applicant's note that the copy of newly cited reference AM, submitted herewith, is missing two pages. Applicant will obtain and submit a full copy of this reference.

If a fee is required, please charge Deposit Account Number 22-0261 accordingly and notify the undersigned.

Respectfully submitted,

Keith G. Haddaway

Registration No. 46,180

VENABLE

Post Office Box 34385

Washington, D.C. 20043-9998

KGH/sat/::ODMA\PCDOCS\DC2DOCS1\340942\1